Podcasts about Niagara

You know how when you have a good idea, you get a little lightbulb over your head? What if you had a bad idea, and a million cubic feet of rock collapsed on you.On today's episode: why the tourist bureau for today's story drink so much; how the people in today's episode work with equipment that would rattle an melt your skull off and sometimes want to cry and eat each other; and why the phrase “well, I'm glad that's all over” is rarely misapplied this badly.And because you are listening to this as a Patreon supporter, you get to enjoy an additional 10 minutes where we discuss: the hodge podge of brutalized bones and missing appendages that have sailed over the Falls; you'd hear about the increasingly ill-conceived and sketchy reasons people have tried their luck over the Falls on purpose; you would hear the tales of two waterways widely described as “inhospitable to human survival; and you would learn about the only unintentional subaquatic river trolley in the world.Niagara Falls has always been a magnet for honeymooners, daredevils, stunt performers and industrialists, but there is no place more ready to delete you from your travel itinerary in so many permanent and awful ways. It's also been a magnet for nature-inspired calamity. This is our second episode from this exotic location, and I could do an entire episode on just the daredevils alone. I really wanted to record this episode at Niagara Falls, but I also wanted to get it out in the first half of 2025, so no dice. That said, you can't do an episode about Niagara Falls without talking about the numbers of people who “take that vertical swim” on purpose.If you or someone you know sounds like they'd like to visit the Falls so-to-speak, please don't hesitate to reach out. There are people ready to help.In Canada, Talk Suicide Canada at 1-833-456-4566 (Available 24/7) or text 45645, or visit www.crisisservicescanada.ca. For youth and young adults, there is also Kids Help Phone at 1-800-668-6868 or text CONNECT to 686868.In the United States, you can call the 988 Suicide & Crisis Lifeline: just dial 988 (Available 24/7) or you can text HOME to 741741In the UK, you can reach the Samaratins at 116 123.Obviously, this kind of thing that can be hard to talk about, but this is a show filled with things that can be hard to listen to. You're already brave. Use that bravery to pick up a phone and please take care of yourself. All older episodes can be found on any of your favorite channelsApple : https://tinyurl.com/5fnbumdw Spotify : https://tinyurl.com/73tb3uuw IHeartRadio : https://tinyurl.com/vwczpv5j Podchaser : https://tinyurl.com/263kda6w Stitcher : https://tinyurl.com/mcyxt6vw Google : https://tinyurl.com/3fjfxatt Spreaker : https://tinyurl.com/fm5y22su Podchaser : https://tinyurl.com/263kda6w RadioPublic : https://tinyurl.com/w67b4kec PocketCasts. : https://pca.st/ef1165v3 CastBox : https://tinyurl.com/4xjpptdr Breaker. : https://tinyurl.com/4cbpfayt Deezer. : https://tinyurl.com/5nmexvwt Follow us on the socials for moreFacebook : www.facebook.com/doomsdaypodcast Instagram : www.instagram.com/doomsdaypodcast Twitter : www.twitter.com/doomsdaypodcast TikTok : https://www.tiktok.com/@doomsday.the.podcast If you like the idea of your podcast hosts wearing more than duct tape and bits of old Halloween costumes for clothes and can spare a buck or two, you can now buy me a coffee at www.buymeacoffee.com/doomsday or join the patreon at www.funeralkazoo.com/doomsday

Dateline: June 20, 2025. Rossifari Zoo News is back with a round up of the latest news in the world of zoos, aquariums, conservation, and animal weirdness!   We start off with a quick catch up on me. We then move on to our births for the week, featuring animals from Aquarium of Niagara, Southwick's Zoo, Zoo Miami, Sequoia Park Zoo, Franklin Park Zoo, Minnesota Zoo, Binder Park Zoo, and more.We then say goodbye to animals from Buttonwood Park Zoo, Denver Zoo, Hogle Zoo, Adelaide Zoo, and Chattanooga Zoo.We have additional Zoo News stories from the Columbus Zoo, Smithsonian's National Zoo, Perth Zoo, Fort Worth Zoo, Trevor-Lovejoy Zoo, and more! Conservation News stories includes updating pangolin protections, a rediscovery, and more! And in Other News, it's Ed the zebra.ROSSIFARI LINKS: patreon.com/rossifari to support the pod rossifari.com @rossifari on socials @rossifaripod on TikTok 

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us. This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in bladder cancer; CHECKMATE 214; LITESPARK-005 and LITESPARK-004, showcasing belzutifan's promise; and KEYNOTE-564, adjuvant therapy for kidney cancer. Stay tuned for an insightful conversation on how these trials may be transforming patient outcomes!Studies discussed in the episode:CHECKMATE 901NIAGARACHECKMATE 214CREST trialSEAR 02LITESPARK 004/005AMPLITUDEJAVELIN MEDLEYFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

What were the key challenges and breakthroughs that shaped the BC and Ontario wine industries in the 1980s and 90s? What makes or breaks a new wine project, and why is finding the right vineyard often the most time-consuming step? What made Peter believe that Niagara-on-the-Lake could produce exceptional Chardonnay? In this episode of the Unreserved Wine Talk podcast, I'm chatting with Ann Sperling & Peter Gamble. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Highlights What was Ann's best memory from growing up on the farm? When did Ann and Peter know that they wanted to work in the wine industry? How did Ann and Peter meet? What was the first bottle of wine Ann and Peter shared? How do Ann and Peter navigate their interwoven personal and professional lives? How do they negotiate professional disagreements, and who chooses the wine for dinner? What were the major challenges and opportunities in the BC and Ontario wine industry in the 1980s and 90s? In the early days, how did Peter envision the future of Ontario wines? What are some of the reasons certain vintages almost didn't make it into the bottle? What do you look for when considering a new project? What makes Ann and Peter different from the stereotypical flying winemakers? What were the signs that Niagara-on-the-Lake could produce exceptional Chardonnay? How has working on a small, focused vineyard impacted Ann and Peter's winemaking choices? Why must you suffer to make top-notch wines?   Key Takeaways It was in the early 80s in BC and maybe slightly before that in Ontario, that estate wineries became a thing. Prior to that, that meant there were a few really large wineries, not really making estate or single vineyards. Vineyards were a source of bulk wine for the most part. The hunt for the vineyard became a very important one. We looked at over 230 vineyards before we found one. I think everyone there was on the verge of giving up on this, thinking “Well, they're not really going to buy anything.” Because we'd get it to a certain stage, then we do soil analysis, and we weren't quite happy, or we talked to people who had made wine from the vineyard or something would come up, and we just wouldn't quite be where we wanted to be with the quality of the vineyard. I often work on the basis of paradigms, where I'll take a look at a wine sold throughout the world and say, you know, I think this could be done really well in this area. You know what it is you might be able to accomplish within the parameters that you have - the obvious things, the terroir, the exposures to soils, the temperatures in general.   About Ann Sperling & Peter Gamble Often referred to as the “power couple” of the Canadian wine industry, Peter Gamble and Ann Sperling have long pursued the pinnacles of wine quality in Canadian vineyards and wineries. Following her upbringing on her family's Okanagan Valley vineyard, Ann turned to the soil for the character and complexity of her wines. Acknowledged as a Canadian pioneer of organic and biodynamic viticulture, ‘terroir' was at the centre of her philosophy and she is renowned for her head winemaking roles at Malivoire, Southbrook, and Sperling Vineyards. Peter, a lifetime wine industry professional, has worked alongside Canada's most passionate winemakers to achieve greater heights with our finest appellation wines. Since 2000, Peter has provided expertise in ultra-premium winemaking operations, including: Stratus, Ravine, Benjamin Bridge and Lightfoot & Wolfville. With the purchase of a top-flight ancient Malbec planting in Mendoza, Argentina, in 2008, Ann and Peter broadened their winemaking activities, but Niagara remains their cherished home base. Current focus is on these Niagara projects: On Seven, Lailey and Stonebridge Vineyards and Dobbin Estate.         To learn more, visit https://www.nataliemaclean.com/342.

News; birthdays/events; recent college grads say this is more anxiety inducing than breaking up with someone; word of the day. News; game: quiz; game: feud; (aside from religious books) are there books that changed your life/how you think about things? News; how would you feel if your favorite food/candy was declared "unsafe"?; sitting in a hot tub and/or sauna is just as effective as 30 minutes of exercise...would you do that instead?; do you work harder on Mondays then trail off by Fridays? News; game: calendar trivia; do you go to the movies to see all those "anniversary re-releases"? goodbye/fun facts....international waterfall day...Waterfalls have a way of stopping us in our tracks. International Waterfall Day invites everyone to pause and marvel at these natural wonders. From the roar of Niagara to the misty veil of Angel Falls, each cascade tells its own story. It's not just their beauty but also their role in our world. They provide fresh water, support wildlife, and draw visitors from all corners. Find a nearby waterfall trail and hit the path. If travel isn't an option, stream waterfall videos or documentaries.

Don't let the sad state of mankind discourage you – let that fact energize your sharing of the gospel. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

On this weeks bonus episode of OFF MIC we talk about jerks who send food back, we find out about Lew's body hair regiment and Jason wants to murder fans. Good times.

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

Send us a textJochen Weigel from Stuttgart, Germany joins us to discuss his innovative contributions to prosthetics, including post-processing for Niagara feet and the development of the AirFit casting system.• Jochen's journey from clinical specialist to R&D manager to starting his own business 13 years ago• The AirFit system uses air pressure instead of water to create comfortable prosthetic sockets• Air pressure uniquely compresses only soft tissue while preserving bony structures• Testing in Kenya combined the AirFit system with low-temperature thermoplastic sockets for immediate fitting• The Niagara foot provides exceptional durability compared to SACH feet commonly used in developing regions• Made with special DuPont material (Hydrel) through a complex molding process few can replicate• The foot works across weight ranges from 70-190 pounds when properly tuned• High initial cost compared to $20 Chinese alternatives creates adoption challenges despite long-term savings• Ways to help include volunteering with NGOs, making targeted donations, or collaborating with small companiesIf you have ideas for prosthetic products that could help in developing regions, reach out to smaller companies who are more likely to be interested in humanitarian solutions.Special thanks to Advanced 3D for sponsoring this episode.Support the show

This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others. 

Send us a textStanding at the edge of a thundering cascade, feeling the cool mist on your face as water tumbles over ancient Canadian Shield rock—there's something viscerally satisfying about experiencing a waterfall that enhances any camping adventure. We've assembled our ultimate guide to Ontario's most spectacular waterfalls, all conveniently located within the provincial park system.From the dramatic 40-meter drop of Kakabika Falls (deservedly nicknamed "Niagara of the North") near Thunder Bay to the intimate and family-friendly Stubbs Falls at Arrowhead Provincial Park, each waterfall offers a unique experience. We share our firsthand experiences at locations like Stubbs Falls, where the bubbling pool at the base creates a natural "hot tub" effect before you stretch out on sun-warmed granite rocks. However, we also discuss important safety considerations after witnessing a frightening slip that fortunately ended without serious injury.For those willing to venture further into Ontario's wilderness, we explore options ranging from the moderate three-kilometer hike to High Falls in Algonquin (perfect for swimming and sunbathing) to the much more challenging multi-day trek required to reach the remote Hendrie River Waterfalls in Lake Superior Provincial Park. We've included practical advice about the best seasons to visit (spring for water volume, fall for colors), accessibility considerations, what to pack, and the importance of proper footwear on potentially slippery trails. Whether you're planning a dedicated waterfall adventure or simply looking to enhance an existing camping trip, these seven spectacular destinations offer something for every outdoor enthusiast.Connect with us on social media or email us at hi@supergoodcamping.com with questions or to share your own waterfall experiences. We're taking a brief summer hiatus after our next three episodes to focus on our own camping adventures, but we'll be back in the fall with more outdoor inspiration!Support the showCONNECT WITH US AT SUPER GOOD CAMPING:Support the podcast & buy super cool SWAG: https://store.skgroupinc.com/super_good_camping/shop/homeEMAIL: hi@supergoodcamping.comWEBSITE: www.supergoodcamping.comYOUTUBE: https://www.youtube.com/channel/UCqFDJbFJyJ5Y-NHhFseENsQINSTAGRAM: https://www.instagram.com/super_good_camping/TWITTER: https://twitter.com/SuperGoodCampinFACEBOOK GROUP: https://www.facebook.com/groups/SuperGoodCamping/TIKTOK: https://www.tiktok.com/@supergoodcamping Support the show

Buffalo Mayor Chris Scanlon announces the site of the new Buffalo Animal Shelter on Niagara Street in the city's Upper West Side full 828 Mon, 09 Jun 2025 17:00:23 +0000 FqUuErzPgYJbUMTiPbQ8Wm5FQK6y2jZo buffalo,news,wben,chris scanlon,buffalo animal shelter,news & politics WBEN Extras buffalo,news,wben,chris scanlon,buffalo animal shelter,news & politics Buffalo Mayor Chris Scanlon announces the site of the new Buffalo Animal Shelter on Niagara Street in the city's Upper West Side Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News

Liberty Dispatch Interviews ~June 07, 2025In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics. In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources: Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/; SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Liberty Dispatch Interviews ~June 07, 2025 In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics.  In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources:  Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/;  SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS:  LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

Liberty Dispatch Interviews ~June 07, 2025In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics. In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources: Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/; SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Concluding their three-episode series filmed live in Chicago, your hosts wrap up the weekend with a discussion of the key bladder cancer presentations from the 2025 ASCO Annual Meeting. They begin in the perioperative space, reviewing updated CREST data presented since AUA and revisiting the NIAGARA trial last seen at ESMO 2024, and end by covering the latest EV-302 updates in the metastatic setting.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Our new weekly bonus podcast called OFF MIC. Yes we still use microphones, it's just means not on the radio. Like off camera stuff, but on camera, and on mic...YOU SHUT UP! 

Lucille Esler is a 14-year-old titleholder proudly representing Gloversville, New York, as Miss Niagara's Teen. A student at Gloversville High School, Lucille is a dedicated scholar and community leader with aspirations of becoming a radiologist.Her Community Service Initiative, “Life With Theodorable: Supporting Autistic Individuals and Their Families,” reflects her passion for inclusion and advocacy. As the founder of this initiative, Lucille has raised over $4,000 to provide essential resources and support to autistic individuals and their loved ones. Her efforts have earned her the Glove City Coalition Youth Community Engagement Award.Lucille stays active as a clarinetist, slalom water skier, and board member of her school's Key Club. She is also involved with the Future Business Leaders of America and swims for her school's varsity team. She's no stranger to the spotlight, having played roles like “Darla” in Finding Nemo and “Fiyero” in Wicked.Health and well-being are priorities for Lucille, who practices dance and acrobatics nearly every day. She maintains both her physical and mental health through movement, a healthy diet, and outdoor activities like hiking. Her commitment aligns closely with the values of #MissAmericaFit.Aside from her own initiative, Lucille is passionate about addressing the impact of digital communication on her generation. She believes fostering face-to-face interactions is crucial in an age dominated by screens.To learn more about Lucille's organization follow her on social media at @MissNiagaraTeenNY and check out all the details here: https://lifewiththeodorable.com/Follow us on Instagram @oneworldonefuturepodcast to be the first to know when new episodes drop! And don't forget to follow our host, Ashley, at @itsashleynevison for even more updates and behind-the-scenes content!

Thrilled to have had the chance to sit down with one of the Ontario wine legends, J-L Groux from Stratus Vineyards.  Loved hearing Groux's stories from family trips to Loire buying wine barrels as a child to having the freedom of making the wines he loves in Niagara.

On this episode of Destination on the Left, I talk with Patrick Keyes, Sales and Marketing Manager at Rainbow Air Helicopter Tours in Niagara Falls, about why he believes in coopetition and how collaborations with his competitors have helped him be successful. Patrick explains why being a first call partner to your local and regional DMO is so important, and how you can position yourself to be that partner. He also offers valuable advice on how to work collaboratively at trade shows to build success. What You Will Learn in This Episode: How Patrick developed a regional, visitor-centric mindset by looking beyond traditional industry boundaries Why Patrick firmly believes that coopetition drives success for individual businesses and the broader destination What innovative steps Rainbow Air Helicopter Tours is taking to transform into a year-round, multifunctional attraction, including their new facility and virtual reality experiences Why partnering with local and regional DMOs (Destination Marketing Organizations) allows you to maximize marketing opportunities and industry influence Strategies Patrick uses when attending industry trade shows to represent both his own company and the wider Niagara region, and how this approach builds stronger relationships How Patrick seeks out unconventional partnerships, like collaborations with wineries and golf courses, to create memorable experiences and extend visitor stays in the region Leveraging Collaboration for Year-Round Tourism One of Rainbow Air's boldest moves has been the development of a new 30,000-square-foot tourism center. This ambitious facility isn't just a ticket counter; it's set to become a hub of activity through every season. Traditionally, tourism in Western New York peaks from Memorial Day to Labor Day, but Patrick and his team saw the need for more. The new tourism center, set to open over Memorial Day weekend, will feature a range of amenities, including gift shops, restrooms, and innovative virtual reality attractions, such as parasailing over Niagara Falls. By offering a range of experiences and amenities, Rainbow Air aims to both attract off-peak visitors and encourage them to extend their stays, laying the groundwork for sustainable year-round tourism. The Power of Partnerships A recurring theme throughout Patrick's career is the essential role of strong relationships with Destination Marketing Organizations (DMOs), regional partners, and fellow attractions. As part of Rainbow Air, he is able to attend trade shows globally, but Patrick insists on representing the region, not just his company. “Know your audience, do your research, and come prepared to advocate for not only your attraction, but complementary experiences that round out the destination,” he advises. Forming partnerships with other attractions enables a rising tide that lifts all ships. Being proactive, communicating openly, and showing a genuine commitment to representing the community as a whole are so important. When DMOs trust that you'll be a reliable, high-quality option, you're top of mind for press trips, FAM tours, and state-led opportunities. Creative Collaborations Rainbow Air's vision for cross-industry cooperation doesn't stop at helicopter tours. Patrick is exploring partnerships with local wineries, golf courses, and historical sites. Imagine custom packages where visitors enjoy an aerial tour before being whisked away to a vineyard for a picnic. Or collaborating with the local wine trail for multi-stop experiences. By thinking creatively about what both locals and travelers want, Rainbow Air extends an invitation for everyone to participate in the region's success. What excites Patrick most is not just Rainbow Air's growth, but the chance to be “a beacon” for others in Niagara Falls. By investing in innovation and actively inviting everyone to the table, he hopes to create a mutually beneficial model, one where attractions, large and small, lean on each other to make the region irresistible and vibrant, every season of the year. Resources: Website: https://www.rainbowairinc.com/ LinkedIn: https://www.linkedin.com/in/patrick-keyes-1001186/ We value your thoughts and feedback and would love to hear from you. Leave us a review on your favorite streaming platform to let us know what you want to hear more o​f. Here is a quick tutorial on how to leave us a rating and review on iTunes!

Today, we're going to witness a light so bright it would instantaneously and irreversibly turn your corneas into charcoal, and oddly, it's the least dangerous thing about our story. On today's episode: why the tourist bureau for today's story drink so much; how the people in today's episode work with equipment that would rattle an melt your skull off and sometimes want to cry and eat each other; and why the phrase “well, I'm glad that's all over” is rarely misapplied this badly.And because you are listening to this as a Patreon supporter, you get to enjoy an additional 9 minutes where we discuss: the time we burned down a good chunk of Washington, including the White House; and why you're welcome for it; the time Germany blew up a chunk of New Jersey and Lady Liberty got popped in the boob with a missile; why people through history were ridiculed for believing in waves; and you would hear about an Australian bloke who DIYed himself into one of the most dangerous world records available.This is episode is a staunch reminder of my desire to make sure every episode surprises and delights. A lighthouse? It's not the strangest place we've visited, but it's certainly unexpected. It also checks a lot of boxes for being largely unheard of, bizarre, and forgotten. The Hawaiian experience back in 1946 overwhelmed the public's mind, and no one had time for a building built strong enough to withstand artillery exploding at the touch of mere water. It also hold's a distinction for being a place where people regularly lose it – and we did an episode about an asylum that caught on fire, so that's saying a lot. All older episodes can be found on any of your favorite channelsApple : https://tinyurl.com/5fnbumdw Spotify : https://tinyurl.com/73tb3uuw IHeartRadio : https://tinyurl.com/vwczpv5j Podchaser : https://tinyurl.com/263kda6w Stitcher : https://tinyurl.com/mcyxt6vw Google : https://tinyurl.com/3fjfxatt Spreaker : https://tinyurl.com/fm5y22su Podchaser : https://tinyurl.com/263kda6w RadioPublic : https://tinyurl.com/w67b4kec PocketCasts. : https://pca.st/ef1165v3 CastBox : https://tinyurl.com/4xjpptdr Breaker. : https://tinyurl.com/4cbpfayt Deezer. : https://tinyurl.com/5nmexvwt Follow us on the socials for moreFacebook : www.facebook.com/doomsdaypodcast Instagram : www.instagram.com/doomsdaypodcast Twitter : www.twitter.com/doomsdaypodcast TikTok : https://www.tiktok.com/@doomsday.the.podcastIf you like the idea of your podcast hosts wearing more than duct tape and bits of old Halloween costumes for clothes and can spare a buck or two, you can now buy me a coffee at www.buymeacoffee.com/doomsday or join the patreon at www.funeralkazoo.com/doomsday

Trevor Barrette is a queer theatre maker based in Montreal, known for his kaleidoscopic productions and joy-forward storytelling. A graduate of John Abbott College's Professional Theatre program, he founded the award-winning KaleidoscopeMTL, producing and directing ten productions, including the hit Fringe musical Captain Aurora and the immersive Memento Mori. Trevor's work explores dynamic timescapes, ensemble casting, and enchanting worlds that foster a sense of wonder. Directorial highlights include The Sages of Chelm and The Great Divide for the Dora Wasserman Yiddish Theatre at the Segal Centre, as well as serving as assistant director for Les Belles Soeurs at the Stratford Festival. Trevor has performed with institutions such as the National Arts Centre, Centaur Theatre, Segal Centre, Geordie Theatre and teaches at the Segal Centre Academy and Geordie Theatre School. Currently, he is developing new works, including a musical inspired by Dr. Brenda Milner's legacy. This July, he will direct Hudson Village Theatre's presentation of Bed and Breakfast.Rylan Allen is thrilled to be part of the MAWAM team and to bring this touching, hilarious show to life. Hailing from Hamilton, Ontario, he graduated from Sheridan College's Musical Theatre Program and performed with Canadiana Productions Inc. in Niagara as a performer, dance captain, and choreographer until lockdown. During that time, he discovered a passion for teaching, working as a Music Director for Hamilton's Conservatory for the Arts. Favorite roles include Peter in Jesus Christ Superstar (Brott Music Festival), Noel Gruder in Ride the Cyclone (Playhouse Collective), and Monsieur André in Phantom of the Opera (Theatre Sheridan). Rylan thanks his mentors for sharing their toolboxes with him, the MAWAM team for this incredible experience, and his friends and family for their unwavering support.Émile Auger is a multidisciplinary performer and teacher from Montréal. He began his artistic journey in the music and jazz band program at St-Luc High School. He went on to study musical theatre at Collège Lionel-Groulx's professional theatre program and graduated in the spring of 2022. In 2023, he completed his third and final semester in musical theatre at Sheridan College, Ontario. His performance credits include Jazz Noisette (Les Jeunesses Musicales du Canada), Lucky Stiff (Stephenville Theatre Festival), Rock of Ages (STF), Let's Bop! (Terra Bruce Productions) and Lorenzo Sterzi's latest film, Cadavre Exquis (LostandKik Pictures). Émile is thrilled to make his Segal Center debut as part of this original musical theatre production.Max + Aaron Write A MusicalSet in present-day Montreal, two childhood friends and creative collaborators race against the clock to finish their latest project: a coming-of-age musical loosely based on their lives. But as they deep dive into the work, long-repressed truths rise to the surface and threaten their partnership. A sexy cautionary tale about writing what you know.

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Please join us on the Boardgames To Go discord server where you can chat online with other podcast listeners. Openers: Mark: Space Empires 4X Jonathan: 2005 Flashback & Quiz Closers: Jonathan: My top games of 2005 Mark: Hosting my own (small) event instead of traveling to a con? Mark Johnson @MarkEJohnson Jonathan Takagi @jtakagi The Wayback Machine is back. One more time, a friend joins me to go back in time to an earlier Spiel des Jahres, looking at the winner but also the other nominees and recommended games. In addition, my guest helps me think about the earlier time itself, and how the games, the hobby, and the community may have changed over the years. This time it's my longtime friend & listener from San Diego, Jonathan Takagi. In fact, he's from a bit north, in Escondido, and Jonathan is another one of the people behind my favorite regional con, EsCon. I'll be going back there in a month! Jonathan decided to pick 2005 because it's twenty years ago...which also happens to be when I started the podcast. Niagara was the game that won the SdJ (one of my earliest disappointments with the jury's selection!), and I replayed it just recently to re-examine my opinion about the game. In fact, it can be played online at BGA, which seems odd for a game that relies on its physicality and "toy factor" as much as it does. Still, the actual strategy in the game remains intact in the format, since the unpredictability of the fork in the river may not be so unpredictable after all. What do you think of Niagara?    We don't just talk about the winner, though. Back in those days, the SdJ jury announced four other "nominated" games that could've won the award, and several more "recommended" games. For me, I think the game I'd want as the winner resides in the nominated list, while Jonathan singles out some standouts from the recommended list. Other titles nominated for the SdJ: Verflixxt! (That's Life), Around the World in 80 Days, Jambo, and Himalaya (Lords of Xidit)     Other titles recommended by the SdJ jury: Boomtown, Tanz der Hornochsen (Dance of Ibexes), The Gardens of the Alhambra, Diamant (Incan Gold), Geschenkt! (No Thanks), Piranha Pedro, Typo, and Wie ich die Welt sehe…         We also talk about two other major German game awards, the Deutscher Spielpreis, and the A La Carte. They are both ranked list. The former is (sort of) for heavier, gamer-games, while the latter is for card games (or “board”games done with cards). The timing of these awards is slightly off from the SdJ, so depending on publication dates a game might show up in one year's list for one award, and the following year for another award. But they're all close, and with some notable overlap for widely-respected games. DSP 1. Louis XIV 2. Niagara 3. Manila 4. Ubongo 5. Himalaya 6. Around the World in 80 Days 7. Shadows Over Camelot 8. Jambo 9. The Scepter of Zavandor 10. Verflixxt! A La Carte 1. Jambo 2. Geschenkt! 3. Wie ich die Welt sehe… 4. Diamant 5. Boomtown 6. Razzia! 7. Team Work 8. Gelb Gewinnt! Near the end of the episode, Jonathan considers what we can now observe in the hobby when we look back on 2005. Was it the start of a transition from “German Games” to the broader notion of “Euros”? Of course we had some French, Italian, British, and even American titles back then, but they're hobby still showed its tremendous roots in German culture and its game publishing. At some point, that changed. Was this around the start of that change? -Mark

The National Weather Service calls for mostly cloudy skies this afternoon with a high near 56. It will remain mostly cloudy overnight with a low around 44.  In news, the fire at Lockport's Jiffymart plaza on Thursday was contained to a 750-sqaure-foot area. And damage was limited to just $60,000 according to the Lockport fire department. And there were no injuries reported.  The clerks of Niagara and Orleans counties warn residents to be on the lookout for a couple differnt DMV phishing scams. As a rule, confirm you're talking to who you think you're talking to before giving them money or access to your life.  And in sports, the Bisons fell to the Charlotte Knights, 5-3 on Friday. But they're back at it today. And it's Star Wars night. So they got that going for them. 

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

Dans cette émission, Mathieu Alterman nous fait découvrir les chansons françaises les plus mélancoliques et déprimantes de tous les temps. De Bert Silva à Barbara en passant par Niagara, il nous plonge dans l'univers sombre mais fascinant de ces classiques de la chanson qui ont marqué plusieurs générations. Un voyage musical empreint de tristesse, de nostalgie et de beauté des textes.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Louise Attaque - J't'emmène au vent Kyo - Le Graal Terrenoire - Vivre Sobrement Etienne Daho - Week-End A Rome Calogero - X Vernis Rouge & Zaoui - Comme des loups Mani - Bang Bang Helena - Mélatonine Gérald De Palmas - Sur la route Joseph Kamel Ft. Julien Doré - Beau BB Brunes - Lalalove You Zazie - Un point c'est toi Christophe Willem - Ps Je T'aime Alain Bashung - Vertige De L'amour Simple Plan ; Marie-Mai - Jet Lag Pierre Garnier - Chaque seconde Big Soul - Le Brio Santa - La différence Daniel Balavoine - Je ne suis pas un héros Boulevard Des Airs - Bruxelles Louane - Maman Izia - Mon cœur Lily Allen & Ours - 22 Lisa Pariente - Pas banale Jacques Dutronc - Les Cactus (Live) Clara Luciani - Courage Blonde Amer - Si Jamais Renaud - Morgane De Toi Leman - Les étoiles Niagara - J'ai Vu Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this special Season Finale episode, Brandon Caputo and Cam Halbert discuss the Niagara IceDogs offseason of changes with the pending hiring of a General Manager and Head Coach by welcoming on owner Darren DeDobbelaer to discuss why the changes will be different moving forward from the previous changes, getting the franchise's culture right after the Review from the OHL and making sure the right people are in place to move this young core forward.We also welcome Steven Ellis of Daily Faceoff to discuss the IceDogs upcoming draft eligible players for the 2025 NHL Draft in second-year forward Ethan Czata and draft +1 year defenceman Jack Brauti, as well as how the landscape of junior hockey has changed with the new NCAA Player Agreement, strong OHL Draft class this year and things to look for going forward for top 2026 Draft eligibles in Ryan Roobroeck and Braidy Wassilyn.Segments:Intro 0:00Owner Darren DeDobbelaer: 10:33Steven Ellis of Daily Faceoff: 42:43The Dog Pound Podcast is proudly brought to you by Global Pet Foods' Four Niagara Region locations. Check them out at: https://globalpetfoods.com/Armchair Merchandise Site: https://the-armchair-gms-sports-ne-shop.fourthwall.com/en-cad/== Follow along with our IceDogs Content ==https://x.com/DogPoundPodcasthttps://niagaraicedogs.net/the-dog-pound-podcast== FOLLOW THE NETWORK ==X: https://x.com/ArmchairGMPodTikTok: https://www.tiktok.com/@UCJUaG5QNg1jwQ5a_32rZs1QFacebook: https://www.facebook.com/ArmchairGMsNetworkInstagram: https://www.instagram.com/armchairgmsportsWebsite: https://www.armchairgmsports.com/Threads: https://www.threads.net/@UCJUaG5QNg1jwQ5a_32rZs1Q== ALSO AVAILABLE TO LISTEN TO ON ==Spreaker: https://www.spreaker.com/thearmchairgms​Apple Podcast: https://podcasts.apple.com/us/podcast/the-armchair-gms-sports-network/id1462505333Spotify: http://bit.ly/ArmchairGM​== FOLLOW THE HOSTS ON TWITTER ==Brandon: https://x.com/BCaputo_AGMCam: https://x.com/BCaputo_AGM

In today's episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medical oncology), a professor of urology, director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, and director for Translational Research at The Tisch Cancer Institute in New York, New York. In our exclusive interview, Dr Galsky discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 NIAGARA trial (NCT03732677), and the role of this regimen in the MIBC treatment paradigm, including for cisplatin-eligible patients with mild renal impairment.

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube por pausa arancelaria de Trump: Futuros al alza: $SPX +1.6%, $US100 +1.7%, $INDU +1.4%. Trump retrasa aranceles del 50% a la UE hasta el 9 de julio, lo que alivia el sentimiento del mercado tras una semana negativa. Hoy se publican pedidos de bienes duraderos de abril (estimado: -7.6%) y núcleo (-0.1%), además de la confianza del consumidor de mayo (previsto: 87.1). También se esperan los precios de viviendas S&P Case-Shiller y FHFA. Atentos al reporte de $NVDA este miércoles. • Tesla se desploma en Europa: $TSLA vendió solo 7,261 vehículos eléctricos en abril en Europa (-49% YoY), mientras el sector creció 34.1%. La marca pierde terreno por la controversia política de Musk, el auge de los híbridos (35% del mercado) y la competencia feroz de BYD y otros fabricantes. A pesar de ello, las acciones suben +2.7% premarket. • WeRide acelera en Medio Oriente: $WRD anunció su expansión a Arabia Saudita, con planes de lanzar robotaxis en Riad y AlUla en alianza con la Autoridad General de Transporte. La operación se integrará a la app de $UBER y se espera el despliegue completo para fines de 2025. La empresa también amplía su red a 15 ciudades más junto a $UBER en los próximos cinco años. $WRD +5.7% premarket a $9.63. • AstraZeneca avanza con Imfinzi en cáncer de vejiga: $AZN recibió respaldo positivo del panel de la EMA para su inmunoterapia Imfinzi en combinación con quimioterapia para tratar el MIBC resecable. El estudio fase 3 NIAGARA mostró beneficios en supervivencia libre de eventos y general. Se espera la decisión final de la Comisión Europea. Una jornada con alivio geopolítico, expansión tecnológica y avances farmacéuticos. ¡No te lo pierdas!

The National Weather Service calls for partly sunny skies today with a high near 72. Overnight will be mostly cloudy with a low around 54.  In news, a stolen vehicle chase through Niagara and Erie Counties ended with the arrest of an 18-year-old Buffalo woman. And charges for a 15-year-old and 13-year-old male.  In sports, the Bisons return to action today, hosting the Charlotte Knights at 6:05 p.m. at Sahlen Field. 

Ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types. Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see if the data may represent a new opportunity for this patient population. Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for those with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations. Additionally, Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for those with extensive-stage small cell lung cancer (ES-SCLC). According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this SCLC population. In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University School of Medicine in St. Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators of this study evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins noted his excitement to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study. As part of an Oncology Decoded discussion, Benjamin Garmezy, MD, the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

In this Season Finale episode Brandon Caputo and Austin Broad discuss the Buffalo Sabres upcoming Offseason activity including the NHL Draft, Free Agency, Hiring of a Senior Advisor as well as the decisions to retain GM Kevyn Adams and HC Lindy Ruff for next season; plus go over Fan Poll results. SegmentsIntro: 0:00Reacting to Adams and Ruff returning: 02:40Senior Advisor Possibilities: 07:35What to do with 9th overall: 29:00Sabres Offseason needs: 41:50Sabres Semantics is proudly brought to you by the Niagara Employment Help Centre: Helping people find work in Niagara since 1983. Check out their up-to-date job board at ehc.on.ca to find your next work opportunity today!Promotion with Hockeystickman for $15 off your first registered order:hockeystickman.ca/thearmchairgmIntro Songs Credit:Ivan from Guitar Logic: https://www.youtube.com/watch?v=Bmy9KGCcfVAJoe Bucci: https://www.youtube.com/watch?v=L5ZiMjXQDtY&t=1sPicture Credit: Micheline: https://x.com/MiMiV4682== FOLLOW THE NETWORK ==X: https://x.com/ArmchairGMPodTikTok: https://www.tiktok.com/@UCJUaG5QNg1jwQ5a_32rZs1QFacebook:  https://www.facebook.com/ArmchairGMsNetwork/Instagram: https://www.instagram.com/armchairgmsnetwork/Website: https://www.armchairgmsports.com/== ALSO AVAILABLE TO LISTEN TO ON ==Spreaker: https://www.spreaker.com/thearmchairgms​Apple Podcast: https://podcasts.apple.com/us/podcast/the-armchair-gms-sports-network/id1462505333?uo=4Spotify: http://bit.ly/ArmchairGM​Amazon Music: https://music.amazon.ca/podcasts/f69c2372-97f9-4c0e-8d52-ade7d7591cd4/the-armchair-gm's-sports-network== FOLLOW US ON TWITTER == Brandon Caputo: https://x.com/BCaputo_AGMAustin Broad: https://x.com/Austin_BroadSabres Semantics: https://x.com/SabresSemantics

Big Soul - Le Brio Guillaume Grand - Toi & Moi Benjamin Biolay - Juste Avant De Tomber Etienne Daho - Des Heures Hindoues Marine - Ma Faute Dua Lipa & Pierre De Maere - These Walls Corson - Raise Me Up (Je Respire Encore) Vianney - Hallelujah (Radio Edit) Au P'tit Bonheur - J'veux Du Soleil Charlotte Cardin - Feel Good Lily Allen & Ours - 22 Tryo - L'hymne de nos campagnes James Blunt Feat Léa Paci - Cold Alain Bashung - Gaby Oh Gaby Louise Attaque - Chaque jour reste le nôtre Clara Luciani - Tout pour moi Lilicub - Voyage En Italie Cœur De Pirate - Cavale Jean-Jacques Goldman - Elle a fait un bébé toute seule Ade - Dissimule St Graal - Je t'emmènerai Gerald De Palmas - Au Paradis Jérémy Frerot - Avec Ou Sans Helena - Mauvais Garçon Jean Leloup - 1990 Boulevard Des Airs - Je Me Dis Que Toi Aussi Renaud - Dès que le vent soufflera Aline - Elle m'oubliera Jean-Louis Aubert - Tout Y Est Niagara - Pendant que les champs brûlent Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

On today's edition of Producer's Picks of the Week, we bring you two segments from episodes that aired this week.

On today's show we welcome back two familiar voices from Niagara Pride: President and Co-Founder Ronald Piaseczny, and Programming Chair Sherry Fossett. Niagara Pride is a nonprofit dedicated to uplifting the LGBTQIA2S+ community across Niagara County and Western New York. Their mission? To create a region where everyone, individuals and families alike, can feel safe, supported, and celebrated in every space they occupy, from home to workplace, places of worship, and beyond. This grassroots organization is working hard to make Pride more visible and more accessible, especially in rural communities that often get overlooked. Ronald and Sherry join Jay Moran to share what's coming up — including the Pride Flag Raising Across Niagara County on May 30, and Niagara Pride's participation in the Buffalo Pride Parade on June 1.

Niagara - J'ai Vu Justin Nozuka Feat Zaho - Heartless Terrenoire - Vivre Sobrement Indochine - Trois Nuits Par Semaine Solann - Les Ogres Helena - Mauvais Garçon Noa Moon - Paradise Cobalt - Sincère -M- - Je dis aime Charlotte Cardin - Feel Good Luke - La Sentinelle Jean-Jacques Goldman - On ira Josiane - Lose It All Olivia Ruiz - Mon Corps Mon Amour Jean-Louis Aubert - Saute Gérald De Palmas - Sur la route Lisa Pariente - Pas banale Marc Lavoine - Pour une biguine avec toi Izia - La vague Styleto - Amour Cyclone Clara Luciani - Tout pour moi David Hallyday - Tu ne m'as pas laissé le temps Santa - La différence Dua Lipa & Pierre De Maere - These Walls Vanessa Paradis - Tandem Francis Cabrel - Sarbacane Zazie - Rodéo Leman - Les étoiles Daran et les chaises - Dormir dehors Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

This week features Simon Rakoff and Monica Gross!From Accent on Toronto, Simon shares his tales of performing in every little town in this country. And from Niagara-on-the Lake, Monica Gross asks the question “what do normal people do to be happy?” 

Dateline: May 9, 2025. Rossifari Zoo News is back with a round up of the latest news in the world of zoos, aquariums, conservation, and animal weirdness!   We start off with our usual introduction, talking a bit about me. We then move on to our births for the week, featuring animals from Zoo Duisburg, the San Diego Zoo and Safari Park, Abilene Zoo, the Bronx Zoo, Aquarium of Niagara, and Cleveland Metroparks Zoo! We say goodbye to beloved animals at Zoo Boise, the Toledo Zoo, Utica Zoo, the Arizona-Sonora Desert Museum, and the Oregon Zoo.The rest of our Zoo News stories feature items from Mote Marine Lab, Zoos Victoria, Brevard Zoo, the St. Louis Zoo, the Cincinnati Zoo, and the reveal of the latest SAFE Program! Then in Conservation News we have multiple rediscoveries, multiple stories focused on how new technologies are helping save species, and a discussion about the video game Fortnite!In Other News, we talk about a guy who got bit by a lot of snakes and more! ROSSIFARI LINKS: patreon.com/rossifari to support the pod rossifari.com @rossifari on socials @rossifaripod on TikTok 

Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial. Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy. Key topics covered in this episode: •⁠  ⁠Overview of the NIAGARA trial and its findings •⁠  ⁠Comparison of Durvalumab and cisplatin-based chemotherapy outcomes •⁠  ⁠The significance of event-free survival and overall survival rates •⁠  ⁠Insights on managing side effects and treatment sequencing •⁠  ⁠The evolving role of ctDNA in determining treatment strategies YouTube: https://youtu.be/s_tXoX5yhV8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals! #OncologyBrothers #BladderCancer #Dervalumab #FDAApproval #NiagaraTrial #Immunotherapy #CancerResearch #OncologyPodcast